JSPR (Jasper Therapeutics) EBIT : $-82.97 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics EBIT?

Jasper Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2025 was $-21.80 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2025 was $-82.97 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jasper Therapeutics's annualized ROC % for the quarter that ended in Mar. 2025 was -1,028.09%. Jasper Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -2,757.57%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jasper Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was -208.50%.

Jasper Therapeutics EBIT Historical Data

The historical data trend for Jasper Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jasper Therapeutics EBIT Chart

Jasper Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

-20.68

-36.83

-51.20

-68.86

-76.24

Jasper Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT	Get a 7-Day Free Trial														-15.07	-15.99	-19.89	-25.29	-21.80

Competitive Comparison of Jasper Therapeutics's EBIT

For the Biotechnology subindustry, Jasper Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jasper Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Jasper Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-82.97 Mil.

Jasper Therapeutics (NAS:JSPR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jasper Therapeutics's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

	ROC % (Q: Mar. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2024 )	+	Invested Capital (Q: Mar. 2025 ))	/ count )
=	-87.208 * ( 1 - 0% )	/	( (8.874	+	8.091)	/ 2 )
=	-87.208	/	8.4825
=	-1,028.09 %

where

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	79.899	-	10.451	-	( 71.637	-	max(0, 15.237	-	75.811	+	71.637	))
=	8.874

	Invested Capital		(Q: Mar. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	57.597	-	8.666	-	( 48.799	-	max(0, 12.334	-	53.174	+	48.799	))
=	8.091

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Jasper Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2024		Q: Mar. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-87.208	/	( ( (2.851 + max(-9.974, 0))	+	(3.474 + max(-6.124, 0)) )	/	2 )
=	-87.208	/	( ( 2.851	+	3.474 )	/	2 )
=	-87.208	/	3.1625
=	-2,757.57 %

where Working Capital is:

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.174)	-	(10.451	+	0	+	3.697)
=	-9.974

	Working Capital		(Q: Mar. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.375)	-	(8.666	+	0	+	1.833)
=	-6.124

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jasper Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2025 )
	=	-82.969	/	39.793
	=	-208.50 %

Jasper Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Jasper Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065

Website

https://www.jaspertherapeutics.com

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Executives

Jeetinder Singh Mahal	officer: Chief Operating Officer	C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Velan Capital Master Fund Lp	other: See Footnote 1	1055B POWERS PLACE, ALPHARETTA GA 30009
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Thomas G Wiggans	director
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ron Martell	director, officer: President, CEO & Director	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker	officer: Chief Medical Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French	director	C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster	director, 10 percent owner	601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Qiming U.s. Healthcare Fund Ii, L.p.	10 percent owner	350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade	10 percent owner	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc	10 percent owner	11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004